journal article·2024-05-15Open access

Engineering H2O2 Self-Supplying Platform for Xdynamic Therapies via Ru–Cu Peroxide Nanocarrier: Tumor Microenvironment-Mediated Synergistic Therapy

Worku Batu Dirersa, Tzu-Chun Kan, Jungshan Chang, Girum Getachew, Sonjid Ochirbat, Shamsa Kizhepat, Aswandi Wibrianto, Akash Rasal, Hung-An Chen, Anil Vithal Ghule, Tzung-Han Chou, Jia-Yaw Chang

ACS Applied Materials & Interfaces· Volume 16· Issue 19

Abstract

High Resolution Image Download MS PowerPoint Slide Of the most common, hypoxia, overexpressed glutathione (GSH), and insufficient H 2 O 2 concentration in the tumor microenvironment (TME) are the main barriers to the advancment of reactive oxygen species (ROS) mediated Xdynamic therapies (X = photo, chemodynamic, chemo). Maximizing Fenton catalytic efficiency is crucial in chemodynamic therapy (CDT), yet endogenous H 2 O 2 levels are not sufficient to attain better anticancer efficacy. Specifically, there is a need to amplify Fenton reactivity within tumors, leveraging the unique attributes of the TME. Herein, for the first time, we design Ru x Cu 1– x O 2 –Ce6/CPT (RCpCCPT) anticancer nanoagent for TME-mediated synergistic therapy based on heterogeneous Ru–Cu peroxide nanodots (Ru x Cu 1– x O 2 NDs) and chlorine e6 (Ce6), loaded with ROS-responsive thioketal (TK) linked-camptothecin (CPT). The Ru–Cu peroxide NDs (RCp NDs, x = 0.50) possess the highest oxygen vacancy (O V ) density, which grants them the potential to form massive Lewis’s acid sites for peroxide adsorption, while the dispersibility and targetability of the NDs were improved via surface modification using hyaluronic acid (HA). In TME, RCpCCPT degrades, releasing H 2 O 2, Ru 2+/3+, and Cu +/2+ ions, which cooperatively facilitate hydroxyl radical (•OH) formation and deactivate antioxidant GSH enzymes through a cocatalytic loop, resulting in excellent tumor therapeutic efficacy. Furthermore, when combined with laser treatment, RCpCCPT produces singlet oxygen ( 1 O 2 ) for PDT, which induces cell apoptosis at tumor sites. Following ROS generation, the TK linkage is disrupted, releasing up to 92% of the CPT within 48 h. In vitro investigations showed that laser-treated RCpCCPT caused 81.5% cell death from PDT/CDT and chemotherapy (CT). RCpCCPT in cancer cells produces red-blue emission in images of cells taking them in, which allows for fluorescence image-guided Xdynamic treatment. The overall results show that RCp NDs and RCpCCPT are more biocompatible and have excellent Xdynamic therapeutic effectiveness in vitro and in vivo.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei 106335, Taiwan, Republic of China

Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan

International Master/Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan

International Ph.D. Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan

Green Nanotechnology Laboratory, Department of Chemistry, Shivaji University, Kolhapur 416004, India

Department of Chemical and Materials Engineering, National Yunlin University of Science and Technology, Yunlin 64002, Taiwan, Republic of China

Funding

National Science and Technology Council of the Republic of China

References (69)

Show source-provided references
1. 10.1002/adfm.20210610610.1002/adfm.202106106 ↗
2. 10.1016/j.actbio.2022.10.00210.1016/j.actbio.2022.10.002 ↗
3. 10.1038/nrd280310.1038/nrd2803 ↗
4. 10.1021/acsami.3c0379210.1021/acsami.3c03792 ↗
5. 10.1021/jacs.7b0730210.1021/jacs.7b07302 ↗
6. 10.1021/acsami.3c0987310.1021/acsami.3c09873 ↗
7. 10.1021/acsnano.0c0135010.1021/acsnano.0c01350 ↗
8. 10.1002/adfm.20190612810.1002/adfm.201906128 ↗
9. 10.1002/adma.20200186210.1002/adma.202001862 ↗
10. 10.1021/acs.nanolett.8b0004010.1021/acs.nanolett.8b00040 ↗
11. 10.1002/adma.20190602410.1002/adma.201906024 ↗
12. 10.1002/adfm.20191008510.1002/adfm.201910085 ↗
13. 10.1002/adma.20200689210.1002/adma.202006892 ↗
14. 10.1016/j.nantod.2020.10085110.1016/j.nantod.2020.100851 ↗
15. 10.1021/acsami.2c2106710.1021/acsami.2c21067 ↗
16. 10.1002/anie.20170289810.1002/anie.201702898 ↗
17. 10.1002/ange.20150047810.1002/ange.201500478 ↗
18. Henderson B. W. · Cancer Res. · 1987 · 47 · 3110
19. 10.1002/anie.20151134510.1002/anie.201511345 ↗
20. 10.1002/adma.20180832510.1002/adma.201808325 ↗
21. 10.1021/acs.chemrev.7b0025810.1021/acs.chemrev.7b00258 ↗
22. 10.1016/j.biomaterials.2018.02.02910.1016/j.biomaterials.2018.02.029 ↗
23. 10.1002/adma.20160386410.1002/adma.201603864 ↗
24. 10.1016/j.biomaterials.2016.07.01010.1016/j.biomaterials.2016.07.010 ↗
25. 10.1038/ncomms978510.1038/ncomms9785 ↗
26. 10.1002/adfm.20150480310.1002/adfm.201504803 ↗
27. 10.1021/jacs.7b1111410.1021/jacs.7b11114 ↗
28. 10.1021/acsami.9b1347010.1021/acsami.9b13470 ↗
29. 10.1021/acsami.3c0722710.1021/acsami.3c07227 ↗
30. 10.1039/C7BM00790F10.1039/C7BM00790F ↗
31. 10.1016/j.actbio.2020.12.03610.1016/j.actbio.2020.12.036 ↗
32. 10.1021/acsami.3c0386310.1021/acsami.3c03863 ↗
33. 10.1073/pnas.170197611410.1073/pnas.1701976114 ↗
34. 10.1021/acsami.1c0241310.1021/acsami.1c02413 ↗
35. 10.1002/adma.20190599410.1002/adma.201905994 ↗
36. 10.1021/acsami.3c0670310.1021/acsami.3c06703 ↗
37. 10.1021/acsnano.8b0099910.1021/acsnano.8b00999 ↗
38. 10.1021/acsami.2c0178210.1021/acsami.2c01782 ↗
39. 10.1002/adma.20130282010.1002/adma.201302820 ↗
40. 10.1021/acs.iecr.1c0435710.1021/acs.iecr.1c04357 ↗
41. 10.1021/acsami.0c2276710.1021/acsami.0c22767 ↗
42. 10.1021/acsestwater.3c0000210.1021/acsestwater.3c00002 ↗
43. 10.1016/j.eurpolymj.2019.04.05010.1016/j.eurpolymj.2019.04.050 ↗
44. 10.1016/j.mtchem.2022.10115810.1016/j.mtchem.2022.101158 ↗
45. 10.1016/j.jcis.2023.05.09910.1016/j.jcis.2023.05.099 ↗
46. 10.1039/C9NR05746C10.1039/C9NR05746C ↗
47. 10.1002/ppsc.20150009810.1002/ppsc.201500098 ↗
48. 10.1021/acsami.3c1073310.1021/acsami.3c10733 ↗
49. 10.3390/pharmaceutics1404083910.3390/pharmaceutics14040839 ↗
50. 10.3390/pharmaceutics1404084710.3390/pharmaceutics14040847 ↗
51. 10.1039/D0NR02527E10.1039/D0NR02527E ↗
52. 10.1021/acsami.1c1310710.1021/acsami.1c13107 ↗
53. 10.1021/acsami.1c0677410.1021/acsami.1c06774 ↗
54. 10.1021/jacs.7b1099710.1021/jacs.7b10997 ↗
55. 10.1021/acsnano.1c0917110.1021/acsnano.1c09171 ↗
56. 10.1016/j.biomaterials.2018.02.01110.1016/j.biomaterials.2018.02.011 ↗
57. 10.1039/D0CS00718H10.1039/D0CS00718H ↗
58. 10.1002/advs.20190059910.1002/advs.201900599 ↗
59. 10.1016/j.cej.2023.14356010.1016/j.cej.2023.143560 ↗
60. 10.1021/ja504298910.1021/ja5042989 ↗
61. 10.1016/j.jphotochemrev.2017.01.00110.1016/j.jphotochemrev.2017.01.001 ↗
62. 10.1016/j.jcis.2023.04.04910.1016/j.jcis.2023.04.049 ↗
63. 10.1002/adfm.20200591810.1002/adfm.202005918 ↗
64. 10.1016/j.biomaterials.2018.12.03210.1016/j.biomaterials.2018.12.032 ↗
65. 10.1021/acsami.1c1964410.1021/acsami.1c19644 ↗
66. 10.1016/j.actbio.2020.07.02210.1016/j.actbio.2020.07.022 ↗
67. 10.1039/c2nr33429a10.1039/c2nr33429a ↗
68. 10.1016/j.ccr.2023.21507310.1016/j.ccr.2023.215073 ↗
69. 10.1021/acsami.1c0774810.1021/acsami.1c07748 ↗